- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 307/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 307/16
Total number of patents in this class: 66
10-year publication summary
|
13
|
4
|
3
|
7
|
6
|
5
|
5
|
6
|
1
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 20458 |
6 |
| Sumitomo Chemical Company, Limited | 8997 |
3 |
| AbbVie S.á.r.l. | 27 |
3 |
| Archer Daniels Midland Company | 1133 |
3 |
| Galapagos NV | 286 |
3 |
| KBP Biosciences Co., Ltd. | 30 |
3 |
| Norbrook Laboratories Limited | 201 |
3 |
| Novartis AG | 11254 |
2 |
| Dart NeuroScience, LLC | 45 |
2 |
| Novira Therapeutics, Inc. | 32 |
2 |
| The Regents of the University of Colorado, a body corporate | 2538 |
2 |
| Lario Therapeutics Ltd | 9 |
2 |
| Merck Sharp & Dohme Corp. | 2216 |
1 |
| Toshiba Corporation | 12076 |
1 |
| Bayer Intellectual Property GmbH | 2568 |
1 |
| Board of Regents, The University of Texas System | 5641 |
1 |
| Takeda Pharmaceutical Company Limited | 2945 |
1 |
| Vertex Pharmaceuticals Incorporated | 1568 |
1 |
| ChemoCentryx, Inc. | 392 |
1 |
| Cytokinetics, Inc. | 268 |
1 |
| Other owners | 24 |